Semaglutide acutely reduced blood pressure in normotensive and hypertensive male mice through vascular smooth muscle cell GLP-1 receptor signaling, but not in mice lacking this receptor, indicating VSMC GLP-1R is essential for semaglutide-mediated blood pressure reduction.
Does semaglutide reduce blood pressure in mice through the vascular smooth muscle GLP-1 receptor?
Semaglutide lowers blood pressure and promotes natriuresis via GLP-1 receptors on vascular smooth muscle cells, providing a mechanistic basis for the cardiovascular benefits of GLP-1 receptor agonists.
Effect estimate: BP reduction abolished in Glp1rVSM-/- mice but present in controls (Glp1rVSM+/+)
GLP-1 receptor (GLP-1R) agonists decrease blood glucose and body weight and reduce rates of cardiovascular and renal disease. Although GLP-1R activation lowers blood pressure (BP), the underlying mechanisms remain incompletely understood and have been attributed to weight loss and endothelial cell GLP-1R signaling. Here, we show that GLP-1Rs in vascular smooth muscle cells (VSMCs) are essential for semaglutide-mediated BP reduction in mice. In contrast, GLP-1Rs in Tie2+ endothelial or immune cells are not required for semaglutide to lower BP. The VSMC GLP-1R is dispensable for the effects of semaglutide on food intake, body weight, and blood glucose, but is required for its actions to increase glomerular filtration rate and promote natriuresis. Systemic semaglutide administration resulted in proteomic changes in the renal artery and kidney in pathways related to platelet aggregation, fibrin clot formation, lipid metabolism, and pro-apoptotic signaling that are abolished in mice lacking VSMC GLP-1R expression. Moreover, semaglutide directly induced vasorelaxation in pre-constricted mesenteric arteries ex vivo. Together, these findings identify VSMCs as a key cellular target linking GLP-1R activation to BP regulation, renal electrolyte excretion, and proteomic changes in renal artery and kidney.
Medak et al. (Tue,) conducted a other in Male normotensive and hypertensive mice with conditional inactivation of GLP-1 receptor in vascular smooth muscle cells (Glp1rVSM-/-) and control mice. Semaglutide vs. Vehicle (phosphate-buffered saline) was evaluated on Change in blood pressure (systolic, diastolic, mean arterial pressure) (BP reduction abolished in Glp1rVSM-/- mice but present in controls (Glp1rVSM+/+)). Semaglutide acutely reduced blood pressure in normotensive and hypertensive male mice through vascular smooth muscle cell GLP-1 receptor signaling, but not in mice lacking this receptor, indicating VSMC GLP-1R is essential for semaglutide-mediated blood pressure reduction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: